SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: Vidpok1 who wrote (4103)2/1/2016 6:51:18 PM
From: Biomaven2 Recommendations

Recommended By
DonShimoda
tktom

  Read Replies (1) | Respond to of 4474
 
>>For the purposes of establishing a buyout price 788 should have a substantial impact if the drug may be used for an unmet need by over 20,000 people.

Pharma is simply not going to pay up for a preclinical compound no matter what the preclinical data shows. Would only move the needle once they show some safety and efficacy in the clinic.

Peter



To: Vidpok1 who wrote (4103)2/1/2016 6:58:26 PM
From: trading_cyclist  Respond to of 4474
 
I completely agree.